Executive Director, Internal Audit, Business and Operational Audit
Revolution Medicines
Summary
The Executive Director, Internal Audit will serve as a founding member of the Internal Audit leadership team responsible for managing independent assurance and advisory work that helps a rapidly growing global biotechnology company execute its strategy, scale its operations and deliver medicines to patients. The role reports to the Vice President of Internal Audit.
Job description
The Opportunity
The Executive Director, Internal Audit will serve as a founding member of the Internal Audit leadership team responsible for managing independent assurance and advisory work that helps a rapidly growing global biotechnology company execute its strategy, scale its operations and deliver medicines to patients. The role reports to the Vice President of Internal Audit.
Responsibilities
- Manage strategy, goals and methods for business and operational audits while aligning timely coverage across processes to company priorities. Assess dependencies across research, commercial, patient services, manufacturing, supply chain, G&A and third parties while ensuring adequate coverage with specialist assurance teams.
- Develop and maintain a risk-based business and operational audit portfolio aligned with business strategy, enterprise risks, major transformations, and the company's growth and global expansion.
- Assess the assumptions behind business plans and management reporting and evaluate whether measures of effectiveness provide a reliable view of risk mitigation and emerging problems.
- Lead audits from scoping through reporting and follow-up, including clear conclusions, practical recommendations, and validation that agreed actions address the underlying risk.
- Apply expert analytical judgment and innovative methods to identify root causes, assess business exposure and recommend sustainable improvements.
- Lead strategic change in how Internal Audit provides assurance across multiple functions and processes.
- Embed approved AI, automation and analytics in engagement planning, evidence analysis, assessments and reporting.
- Support Audit Committee reporting through the Internal Audit VP.
Leadership and Capabilities
- Business Acumen, Trusted Advisor and Relationship Builder: Partner consistently with company leaders to influence strategy, governance and policy through independent, relevant insight.
- Hands-On Execution: Willingness to execute granular testing and draft documentation directly as the team scales and adapts technology.
Required Skills, Experience and Education
- 15+ years of progressive experience across internal audit, business operations, risk or consulting, including at least 5 years managing complex portfolios in the pharmaceutical or biotechnology spaces.
- Experience with global expansion, commercial evolutions, major transformations or other periods of rapid organizational change.
- Demonstrated ability to assess strategic execution and operating effectiveness beyond financial controls while partnering with leadership on negotiation of critical matters and influence on policy.
- Practical experience applying analytics and AI to business or assurance problems.
Requirements
- 15+ years of progressive experience across internal audit, business operations, risk or consulting
- At least 5 years managing complex portfolios in the pharmaceutical or biotechnology spaces
- Experience with global expansion, commercial evolutions, major transformations or other periods of rapid organizational change
- Demonstrated ability to assess strategic execution and operating effectiveness beyond financial controls
- Experience partnering with leadership on negotiation of critical matters and influence on policy
- Practical experience applying analytics and AI to business or assurance problems
Benefits
- Competitive cash compensation
- Equity awards
- Benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.